₹ 1940.5
Key Takeaways
Risk factor
Negligible price volatility
Profitability factor
Strong margins and returns
About
Lupin Limited, a pharmaceutical company, develops, produces, markets, and sells a range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). It offers formulations for use in the therapeutic areas of cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastrointestinal, anti-infective, nonsteroidal anti-inflammatory drug therapy, respiratory, women's health, and anti-tuberculosis. The company is...
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of LUPIN.NS is 2309 and suggests 19% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in
